Clinical trial · no report yet · Phase 2
KarMMa-2
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
- NCT03601078 ↗
- Completed
- Celgene
- 47 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 28 | |
| Podcasts | 15 | |
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Multi-cohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- bb2121; Lenalomide; Talquetamab
- Arms
- Cohort 1: BB2121 in relapsed and refractory multiple myeloma participants · Experimental
- Cohort 1b: BB2121 with talquetamab in relapsed and refractory multiple myeloma participants · Experimental
- Cohort 2a: BB2121 in multiple myeloma with Autologous stem cell transplantation participants · Experimental
- Cohort 2b: BB2121 in multiple myeloma without Autologous stem cell transplantation participants · Experimental
- Cohort 2c: BB2121 in multiple myeloma participants with inadequate response post ASCT · Experimental
- Cohort 3: BB2121 with lenalidomide maintenance in newly diagnosed multiple myeloma · Experimental
- Enrollment
- 312
- Primary outcomes
- Overall response rate (ORR)- Cohort 1
- Complete response (CR) rate - Cohort 1b, 2a, 2b, 2c, and Cohort 3
- Sponsor
- Celgene
- Start
- Dec 13, 2018
- Primary completion
- Jan 15, 2026
- Results posted
- No
- Registry record
- NCT03601078 · updated Mar 4, 2026